Precision Medicine in Oncology® Articles

Study Finds No Cardiac Toxicity Increase With Trastuzumab in HER2+ Breast Cancer Patients
Trastuzumab did not reduce cardiac function in women with node-positive, HER2+, early-stage breast cancer.
FDA Expands Afatinib's Approval for Lung Cancer
The FDA has expanded the frontline indication for afatinib to include the treatment of patients with metastatic non–small cell lung cancer whose tumors harbor uncommon EGFR alterations in L861Q, G719X, and/or S768I.
 
Novel Treatments Emerging in HER2+ Breast Cancer Pipeline
Aleix Prat, MD, PhD, discusses the novel treatments being developed in the paradigm of HER2-positive breast cancer.
Pertuzumab and Other Agents Continue Progress in HER2+ Breast Cancer
Adam M. Brufsky, MD, PhD, discusses the developing role of pertuzumab in HER2-positive breast cancer, as well as the impact of other agents in the field.
Dual HER2 Blockade Superior for PFS in HER2+/HR+ Metastatic Breast Cancer
The combination of lapatinib, trastuzumab, and an aromatase inhibitor (AI) reduced the risk for death or progression by 38% in women with HER2+/HR+ metastatic breast cancer compared with those treated with a targeted agent plus AI.
Long-Term Data Published for Neratinib in HER2+ Breast Cancer
Extended adjuvant therapy with neratinib significantly reduced the proportion of clinically relevant breast cancer relapses without increasing the risk of long-term toxicity.
Biomarker Testing Continues to Develop in NSCLC
Kathryn F. Mileham, MD, discusses the development of biomarker testing for patients with mutated non-small cell lung cancer.
Molecular Testing Advancements Leading Field of GI Cancers
Shirley Michelle Shiller, DO, discusses progress with precision medicine for patients with gastrointestinal cancers.
FDA Approves Adjuvant Pertuzumab Regimen for HER2+ Breast Cancer
The FDA has approved pertuzumab in combination with trastuzumab and chemotherapy as an adjuvant treatment for patients with HER2-positive early breast cancer at high risk for recurrence.
 
CHMP Issues Positive Opinion on Herzuma for HER2+ Breast, Gastric Cancers
The European Union’s CHMP has delivered a positive opinion for Herzuma (CT-P6), a trastuzumab (Herceptin) biosimilar in HER2-positive early breast cancer, metastatic breast cancer, and metastatic gastric cancer.
Publication Bottom Border
Border Publication
x